Castle Biosciences director sells $221,636 in stock
Daniel Bradbury, a director at Castle Biosciences Inc . (NASDAQ:CSTL), recently sold shares in the company totaling $221,636. The transactions, which took place on February 5, involved the sale of ...
Le Lézard14h
Shareholders that lost money on Pacira BioSciences, Inc.(PCRX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") of a class action securities ...
Election countdown: Voting in Assembly District 32 special election in Kern County
Here is a list of poll sites for California’s Assembly District 32 Special Primary Election on February 25:Polls are open on ...
stocknews1d
Is Harmony Biosciences Holdings Inc. (HRMY) a Biotech Stock to Consider?
Harmony Biosciences’ (HRMY) recently released growth plans and pipeline advancements have showcased the company’s dedication ...
Le Lézard1d
The Gross Law Firm Notifies Shareholders of Pacira BioSciences, Inc.(PCRX) of a Class Action Lawsuit and an Upcoming Deadline
The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. . Shareholders who purchased shares ...
Phoenix Rising’s new head coach Pa-Modou Kah says 'familial club' coming together
Phoenix Rising FC’s 2025 preseason has kicked off, marking the debut of new head coach, Pa-Modou Kah, who already likes what ...
Pacira BioSciences, Inc. Is Being Sued For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / February 7, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
Targeted Oncology9d
FDA Grants Orphan Drug Designation to MB-105 for R/R T-Cell Lymphoma
MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...
March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR-T Cell Therapy, for T-Cell Lymphoma
Company prepares to advance to Phase 2 clinical trial in early 2025HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an ...
Fintel on MSN15d
Piper Sandler Initiates Coverage of Bright Minds Biosciences (DRUG) with Overweight Recommendation
Fintel reports that on January 23, 2025, Piper Sandler initiated coverage of Bright Minds Biosciences (NasdaqCM:DRUG) with a Overweight recommendation. Analyst Price Forecast Suggests 72.42% Downside ...